Open Access

Lp(a): from causality to therapy

Event: ESC Congress 2022
Topic: Lipid-Lowering Agents
Session type: Satellite Symposium
Organised by PACE-CME - Supported by an unrestricted educational grant from Novartis, Sanofi, New Amsterdam & other sponsors
Date: 28 August 2022
Time: 10:15 - 11:00

Congress Session

This content is currently on OPEN ACCESS

Sign in to view the resources

4 presentations in this session

Targeting Lp(a) in CV risk reduction: where are we now?

Speaker: Doctor P. Kamstrup (Herlev, DK)
Thumbnail

Lp(a) as independent causal risk factor: why should we focus on testing?

Speaker: Professor F. Kronenberg (Innsbruck, AT)
Thumbnail

Targeting Lp(a): therapeutic insights and novel developments.

Speaker: Professor E. Stroes (Amsterdam, NL)
Thumbnail

Discussion.

Speaker: Professor E. Stroes (Amsterdam, NL)
Speaker: Doctor P. Kamstrup (Herlev, DK)
Speaker: Professor F. Kronenberg (Innsbruck, AT)
Thumbnail

6 speakers from this session

Doctor Pia Kamstrup

Copenhagen University Hospital - Herlev Gentofte, Herlev (Denmark)
3 presentations
0 follower

Professor Florian Kronenberg

Medical University of Innsbruck, Innsbruck (Austria)
4 presentations
0 follower

Professor Erik Stroes

Academic Medical Centre, Amsterdam (Netherlands (The))
24 presentations
0 follower

Professor Erik Stroes

Academic Medical Centre, Amsterdam (Netherlands (The))
24 presentations
0 follower

Doctor Pia Kamstrup

Copenhagen University Hospital - Herlev Gentofte, Herlev (Denmark)
3 presentations
0 follower

Professor Florian Kronenberg

Medical University of Innsbruck, Innsbruck (Austria)
4 presentations
0 follower

This platform is supported by

logo Novo Nordisk